Reliance-owned Karkinos Healthcare completes 100,000+ HPV DNA tests
- Karkinos Healthcare (a Reliance step-down subsidiary) completed HPV DNA screening for over one lakh women across India.
- The programme uses WHO-recommended HPV DNA testing plus a digitally enabled continuum that integrates awareness, screening, tracking, triage, navigation and follow-up to reduce loss to follow-up.
- Implementation covered public-health programmes, public–private partnerships, CSR initiatives, nurse-assisted and self-sampling models, district-level screening and targeted outreach to underserved and high-risk communities.
- Karkinos aims to scale to one million tests next and ultimately to one hundred million, and attributes its approach to scientific leaders including the late Dr R. Sankaranarayanan and Dr Partha Basu of IARC.
Milestone
Karkinos Healthcare, a 100% step-down subsidiary of Reliance Industries Limited, has completed HPV DNA screening for over one lakh women across India, expanding access to high-quality cervical cancer screening and follow-up care.
Care model
The organisation uses World Health Organization-recommended HPV DNA testing combined with a digitally enabled continuum of care that integrates awareness, screening, tracking, triage, navigation and follow-up to address loss to follow-up after positive results.
Implementation and reach
The milestone was achieved through multiple implementation models, including public-health programmes, public–private partnerships, CSR-supported initiatives, nurse-assisted and self-sampling programmes, district-level screening efforts, and focused outreach for underserved and high-risk communities, reaching many women who may otherwise lack access.
Scale and next steps
Karkinos says it will target one million tests next and ultimately one hundred million, and highlights the organisation’s commitment to carrying women through the care pathway from screening to treatment with dignity and sustainability.
Public-health context
The release notes that cervical cancer is largely preventable with timely screening, early detection and appropriate follow-up, and that the programme's learnings and infrastructure can support wider adoption of organised cervical cancer screening and India’s elimination efforts.
Source: Reliance Industries
